Use of Floseal®, a human gelatine-thrombin matrix sealant, in surgery: a systematic review by María Echave et al.
Echave et al. BMC Surgery 2014, 14:111
http://www.biomedcentral.com/1471-2482/14/111RESEARCH ARTICLE Open AccessUse of Floseal®, a human gelatine-thrombin
matrix sealant, in surgery: a systematic review
María Echave*, Itziar Oyagüez and Miguel Angel CasadoAbstract
Background: Surgical bleeding can be associated with an increased risk of morbidity and mortality across all surgical
areas. Thus, numerous products have been developed to achieve haemostasis. A flowable haemostatic matrix such as
Floseal® can quickly and reliably stop bleeding across the full spectrum of bleeding scenarios. The aim of this study was
to systematically review clinical and economic evidence regarding the use of Floseal® in surgical procedures.
Methods: An extensive literature search was conducted in PubMed, EMBASE, and the Cochrane Library over the period
spanning 2003–2013 to identify publications related to Floseal® use in all types of surgical procedures. Case reports and
case series studies were excluded.
Results: A total of 27 papers met the selection criteria and were analysed. In the studies, blood loss and the time to
achieve haemostasis were the most reported outcomes used to assess the efficacy of Floseal®. The majority of
published studies (64%) examined the use of Floseal® compared with conventional methods (such as electrocautery or
suturing). The remaining 36% of the studies evaluated the use of Floseal® compared with other haemostatic agents,
such as Surgicel®, Gelfoam®, and Hemostase®. FloSeal® has been demonstrated to be an efficacious method in surgical
procedures to reduce the time to achieve haemostasis, the frequency of intra- and postoperative bleeding, and the
length of hospital stay, among other primary outcomes, resulting in less consumption of health resources.
Conclusions: The majority of the selected studies confirmed that Floseal® showed improvements over other
haemostatic agents in achieving haemostasis and reducing blood loss.
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Surgery procedures, independently of the type, usually
follow a common approach. The major surgical steps are
incision, dissection, exposure, resection, haemostasis, re-
storing anatomy and closure. Among the procedures,
only anatomy differs, but the challenges are always the
same. The typical surgical challenges are bleeding, heal-
ing complications, leakage and adhesion formation. Im-
properly addressing of these challenges, could impact on
patient outcome such as haemorrhagic shock, blood re-
placement, longer hospital stay in case of bleeding.
Surgical bleeding, concretely, can be associated with
an increased risk of morbidity and mortality across all
surgical areas. In particular, bleeding complications arise
in nearly 30% of surgeries [1].* Correspondence: mechave@porib.com
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unless otherwise stated.Excessive bleeding complicates surgery and often leads
to longer hospital stays, increased healthcare service util-
isation, and higher healthcare costs, among other nega-
tive consequences [1].
The length of hospital stay is approximately 2–2.5
times longer for patients who require blood transfusion
[2]. Efforts to control surgical bleeding and the use of
blood transfusions are thus needed to reduce healthcare
consumption and costs.
The most frequent methods typically used to achieve
haemostasis were pressure (dressings) and sutures, but also
numerous products have been developed to achieve the
same aim by different ways, such as topical haemostatic
agents (HA) (e.g., sponges), thrombin, gelatine-thrombin,
fibrin glue, and other types of surgical sealants [3].
Although there is no consensus on how to best
approach haemostasis, the number of options available to
the surgeon continues to grow. Several factors are. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vices, but the most important are the ability of a product
to achieve and maintain haemostasis and the speed with
which bleeding is controlled [4].
Conventional methods for control bleeding are for ex-
ample electrocautery, suturing, manual compression or
ligatures, among others. Additionally, a broad variety of
haemostatic agents such as vegetal-origin (Surgicel®, Tabo-
tamp®, Hemostase®), fibrin sealants such as Tachosil® or
Tisseel®, different sponge products such as only composed
of gelatine (Gelfoam®), or more specific techniques like
polyvinyl alcohol sponge (Merocel®) and Infrared-sapphire
coagulation which consist on light is converted into ther-
mal energy thus causing coagulation and haemostasis,
have been developed in the last decades.
Gelatine-thrombin matrix sealants are commonly used
intra-operatively acting at the end stage of the coagula-
tion cascade to facilitate fibrin formation, promoting co-
agulation and minimising blood loss. These agents are a
mixture of a flowable gelatine matrix (bovine or porcine)
and a human-derived thrombin component. For example,
Floseal® (Baxter Healthcare Corporation Fremont, CA
94555, USA) and Surgiflo® (Ethicon Endo-Surgery, part of
Johnson & Johnson Company, New Jersey 08876, USA) are
composed of a bovine gelatine matrix and a porcine gelatine
matrix respectively, and are typically prepared immediately
before use and directly injected into the site of bleeding.
Floseal® is indicated in surgical procedures as an ad-
junct to haemostasis when control of bleeding, ranging
from oozing to spurting, by ligature or conventional pro-
cedures is ineffective or impractical.
The aim of the present study was to systematically
review the clinical and economic literature regarding
Floseal® use in any type of surgical procedure.
Methods
Searching
PRISMA recommendations were followed using PRISMA
checklist recorded on Additional file 1. An extensive sys-
tematic literature search was performed in MEDLINE using
PubMed, in EMBASE using OVID, and in the Cochrane
Library. English-language articles published during the last
decade (from 1 January 2003 to 31 August 2013) were iden-
tified. The search targeted published studies presenting any
clinical and/or economic type of evaluation of Floseal® use
during surgical procedures and in which Floseal® was com-
pared with at least one alternative. A secondary search
among the citations of the articles retrieved in the initial
search was performed to ensure that all relevant studies
were included.
Selection
The titles and abstracts of the studies identified by the
search strategy were assessed for potential eligibility andwere subsequently retained if they met the following in-
clusion criteria: (a) reporting clinical and/or economic
outcomes, (b) describing any surgical approach, (c) in-
cluding treatment with Floseal® in comparison with con-
ventional methods or with other HAs, and (d) written in
either English or Spanish.
Abstract and poster publications were only considered
if they were published within the past two years, as in-
formation about ongoing studies may be available as par-
tially published research, such as conference abstracts
[5]. In contrast, case series and case reports were ex-
cluded from the review.
Interventions
Studies investigating surgical interventions using Floseal®
were included. Both laparoscopic and open surgeries
were considered, and no surgical procedures were ex-
cluded, including investigations of Floseal® use for epi-
staxis. The studies were then separately assessed based
on surgery type.
Search strategy
Details of the searches performed in MEDLINE and
EMBASE are shown in Tables 1 and 2, respectively. The
Cochrane Library was explored by entering ‘Floseal’ in
the title, abstract, or keyword field.
Data extraction
Two reviewers screened the references based on the de-
fined inclusion criteria and extracted the data. The data
were collected by one author (ME) and checked by a
second author (IO), and all disagreements were resolved
through discussion.
Results
A total of 525 potential publications from the last dec-
ade (2003–2013) were identified by the search (109
using MEDLINE, 385 using EMBASE, and 31 using the
Cochrane Library). Among the 525 references, 126 were
duplicates (24%) and were subsequently excluded. Add-
itionally, 372 publications were excluded for the follow-
ing main reasons: studies comparing surgical procedures
or examining products other than Floseal®, case reports,
and in vitro and animal studies. Figure 1 shows the flow-
chart of the selection process, indicating the potentially
relevant studies identified, the studies retrieved for more
detailed evaluation, the included studies, and the ex-
cluded studies [6-32].
Included studies
A total of 27 studies were ultimately identified and
selected [6-33]. An overview of the characteristics of
these 27 evaluations, including a total of 39,577 patients
undergoing surgical procedures, is shown in Table 3. Six





1 Surgery ((((surgical procedures, operative
[MeSH Terms]) OR general
surgery [MeSH Terms]) OR
surgery [Subheading]) OR
Thoracic surgery [MeSH terms])
OR colorectal surgery [MeSH
Terms]
2,885,426
2 Thrombin (((thrombin [MeSH Terms]) OR
thrombin [All Fields]) OR factor
viiia [MeSH Terms]) OR factor
viiia [A-ll Fields]
43,985





4 Gelatin ((((((gelatin [MeSH Terms]) OR
gelatin [Text Word]) OR gelatin
sponge, absorbable [MeSH
Terms]) OR gelatin sponge,
absorbable [All Fields]) OR
surgical sponges [MeSH Terms])
OR (surgical [All Fields] AND
sponges [All Fields])) OR surgical
sponges [All Fields]
22,894
5 Final fibrin Fibrin [MeSH] OR fibrinogen
[MeSH]
45,657
6 Sealant Sealant [All Fields] 3,328
7 Floseal Floseal [All Fields] 155
8 Humans Humans [MeSH Terms] NOT
animals [MeSH Terms:noexp]
11,498,554
9 Language (english [lang]) OR Spanish[lang] 18,978,494
10 Matrix and thrombin 780
11 Matrix and gelatin 654
12 Matrix and sealant 109
13 Product Matrix #10 OR #11 OR #12 1,370
14 Thrombin and matrix 780
15 Thrombin and gelatin 353
16 Thrombin and sealant 332
17 Product Thrombin #14 OR #15 OR #16 1,294
18 Product #13 OR #17 1,884
19 Product w/o fibrin #18 NOT final fibrin 1,372
20 Final Product #19 OR Floseal 1,403





#21 NOT “case reports”
[Publication Type]
140
23 Final with dates #22 (“2003/01/01”[PDAT]:
“2013/08/31”[PDAT])
109
Table 2 Search strategy for the EMBASE database
SEARCH DETAILS (24 September 2013) NUMBER OF
ARTICLES
1 exp surgery/ or exp colorectal surgery/ or exp
general surgery/ or exp thorax surgery/
3,293,277
2 su.fs. 1,732,981
3 1 or 2 3,766,104
4 exp thrombin/ 35,438
5 Thrombin.mp. 61,009
6 Factor viiia.mp. or exp blood clotting factor 8a/ 912
7 4 or 5 or 6 61,516
8 Matrix bands.mp. 42
9 exp matrix metalloproteinase/ 17,584
10 Hemostatic matrix.mp. 51
11 8 or 9 or 10 17,677
12 Gelatin.mp. or gelatin sponge/ or exp gelatin/ 27,702
13 Gelatin sponge.mp. 2,463
14 Surgical sponges.mp. or exp surgical sponge/ 953
15 (Surgical and sponges).mp. [mp = title, abstract,
subject headings, heading word, drug trade
name, original title, device manufacturer, drug
manufacturer, device trade name, keyword]
600
16 12 or 13 or 14 or 15 28,917
17 exp fibrin/ 18,545
18 exp fibrinogen/ 46,855
19 17 or 18 60,613
20 sealant.mp. 6,172
21 floseal.mp. 375
22 exp human/ 14,968,402
23 animal/ 1,888,844
24 22 not 23 14,485,903
25 7 and 11 216
26 11 and 16 1,096
27 11 and 20 15
28 25 or 26 or 27 1,290
29 7 and 16 465
30 7 and 20 493
31 25 or 29 or 30 1,044
32 28 or 31 2,118
33 32 not 19 1,745
34 21 or 33 2,010
35 3 and 24 and 34 569
36 Limit 35 to (english or spanish) 540
37 exp case report/ 1,986,006
38 36 not 37 460
39 Limit 38 to yr = ”2003 - 2012” 385
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cedures (22.2%); four, either adenoidectomy or tonsillec-
tomy (14.9%); three, cardiac surgery (11.1%); three,
gynaecologic surgical procedures (11.1%); and one, eye
Figure 1 Flow diagram of the selection process to identify studies to be included.
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studies (11.1%) and one study on thyroid surgery (3.7%)
were identified (Figure 2). Among the 27 studies included,
16 (59%) were randomized clinical trials.
Fourteen studies (51.85%) were conducted in the U.S.,
and the remaining studies were from different countries,
including Italy (4), the United Kingdom (2), Germany
(2), Austria (1), Spain (1), Switzerland (1), Turkey (1),
and Canada (1). In these studies, blood loss and the time
to achieve haemostasis were the most reported out-
comes used to assess treatment efficacy. Other outcomes
included the length of hospital stay (LOS) and postoper-
ative pain.
A synthesis of the selected studies is presented in
Table 3. The population targeted in our review was any
patient undergoing surgical procedures. To aggregate the
results, studies included in this systematic review are
grouped by surgical procedure.
Cardiac and vascular surgeries
Three studies identified in this review investigated the
clinical and economic value of Floseal® in cardiac and
vascular procedures [6-8] (Table 4).
In a retrospective database analysis of a U.S. hospital
database, Krishnan et al. [6] identified 36,950 cases of
cardiovascular surgery with HA use between 2003 and
2006. Three treatment cohorts were compared against a
baseline (n = 7,492) that consisted of the use of any sin-
gle agent other than the following: Floseal® (n = 1,603),Gelfoam® + thrombin (n = 10,348), and Surgicel® + throm-
bin (n = 17,507). Surgeries included in the analysis were
open valvuloplasty, valve replacement, and coronary ar-
tery bypass. The primary outcome of the study was the
LOS. The results showed that Floseal® use was associated
with a lower risk of exceeding the expected LOS (odds
ratio = 0.791, p < 0.01) compared with baseline.
A prospective study conducted in Italy randomised
415 patients undergoing elective primary cardiac and/or
thoracic aortic surgeries including Floseal® use (n = 209)
or an alternative topical HA (n = 206) chosen by the sur-
geon (Surgicel® or Gelfoam®) [7]. Floseal® was associated
with a significantly higher rate of successful haemostasis
and a shorter time to achieve haemostasis (p < 0.001 for
both) in comparison with the other alternatives when
conventional methods failed. Moreover, a significantly
higher number of patients required blood transfusions in
the treatment group (76%) compared with the Floseal®
group (56%) (p < 0.001). In addition, the number of blood
units transfused was significantly higher in the treatment
group than in the Floseal® group (61 vs. 97 blood units,
p < 0.001). Although the rates of revision for bleeding and
of minor complications were not significantly different be-
tween groups in the overall cohort, there were significant
differences in the subgroup of patients with evident intra-
operative bleeding. In this subgroup of patients, 4.5% of
the patients treated with Floseal® required revision for
bleeding, compared with 13.5% in the comparator group
(p = 0.04). Also in this subgroup, minor postoperative
Table 3 Overview of the studies identified
Surgery type Author and year Country Study type (N) Therapy
Cardiac surgery Krishnan 2009 [6] US Retrospective chart study review (36,950) Haemostatic agent
Nasso 2009 [7] Italy Prospective randomised controlled trial (415) Haemostatic agent
Sugarman 2013 [8] US Economic evaluation Haemostatic agent
Gyneacologic surgery Angioli 2009 [23] Italy Prospective randomised controlled trial (20) Conventional method
Raga 2009 [24] Spain Prospective randomised controlled trial (50) Conventional method
Sönmezer 2013 [25] Germany Prospective randomised controlled trial (30) Conventional method
Lacrimal surgery Durrani 2007 [32] UK Cases and controls (20) Conventional method
Orthopaedic surgery Comadoll 2012 [11] US Retrospective chart study review (349) Conventional method
Kim 2012 [9] US Prospective randomised controlled trial (195) Conventional method
Velyvis 2012 [10] US Cases and controls (183) Conventional method
Sinus Surgery Baumann 2003 [19] Switzerland Cases and controls (100) Haemostatic agent
Beyea 2011 [21] Canada Prospective randomised controlled trial (20) Haemostatic agent
Chandra 2003 [16] US Prospective randomised controlled trial (20) Haemostatic agent
Chandra 2005 [17] US Prospective randomised controlled trial (18) Haemostatic agent
Jameson 2006 [20] US Prospective randomised controlled trial (45) Conventional method
Shrime 2007 [18] US Retrospective chart study review (172) Conventional method
Thyroid surgery Testini 2009 [22] Italy Prospective randomised controlled trial (155) Haemostatic agent
Tonsillectomy/adenoidectomy Blackmore 2008 [12] UK Prospective randomised controlled trial (30) Conventional method
Jo 2007 [15] US Prospective randomised controlled trial (68) Conventional method
Mathiasen 2004 [14] US Prospective randomised controlled trial (70) Conventional method
Mozet 2012 [13] Germany Prospective randomised controlled trial (176) Conventional method
Urologic procedures Gill 2005 [26] US Cases and controls (131) Conventional method
Guzzo 2009 [28] US Cases and controls (40) Haemostatic agent
Koni 2012 [27] Turkey Prospective randomised controlled trial (43) Haemostatic agent
Nogueira 2008 [29] US Cases and controls (35) Haemostatic agent
Pace 2010 [30] Italy Prospective randomised controlled trial (30) Conventional method
Waldert 2011 [31] Austria Cases and controls (142) Conventional method
US: United States.
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ciency, and inotropic support lasting for more than
24 hours, occurred in 20.9% of Floseal®-treated patients
compared with 33.6% of patients in the comparator group
(p = 0.04).
The third study was an abstract accepted for poster
publication at the International Society For Pharmacoe-
conomics and Outcomes Research in May 2013 [8] that
assessed the economic value of Floseal® in the US based
on the study endpoints and results of the Nasso study
[7] and quantified the monetary costs associated with
the efficient control of intraoperative bleeding and con-
tributing complications. If FloSeal® was the exclusive
method used to achieve haemostasis in a hospital per-
forming 600 mixed cardiac surgeries annually, outcomes
would be improved and achieved cost savings due to the
242 hours saved in operating room and 33 major and 76
minor complications. Additionally, 54 surgical revisionsfor bleeding and 194 blood transfusions would be
avoided. All of the clinical savings would result in total
net annual savings ranging from $4.3-$7.4 million com-
pared with costs in a comparator group (composed of
60.2% Surgicel® and 39.8% Gelfoam® treatments) in a US
hospital setting.
Orthopaedic surgery
Three publications described US studies performed in
unilateral TKA comparing Floseal® with standard of care
such as the use of electrocautery, suturing, or manual
compression (Table 5). All were US studies, two of them
were prospective and the other one retrospective. In
both the prospective studies the endpoint of measure-
ment of blood loss through drain output was the same
[9,10], however the results were different.
One of the most recent studies [10] showed that the
Floseal® group (n = 83) had significantly less intraoperative
Figure 2 Articles selected and included by surgery type.
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blood transfusion rates (p = 0.004) compared to standard
of care (n = 100), whereas research performed by Kim
et al. [9] did not find significant differences between Flo-
seal® (n = 97) and the control group (n = 99) (electro-
cautery followed by wound closure) in terms of drain
output, transfusion rates, or postoperative pain.
In the retrospective study the principal endpoint was
the measurement of haemoglobin levels, which is an in-
direct way to estimate blood loss in any surgery type [11].
The authors of this retrospective study concluded that
decreases in haemoglobin, both pre- and post-surgery, were
significantly reduced in the Floseal® cohort (n = 184 vs n =Table 4 Cardiac and vascular surgeries
Author and year Comparator and patients
per arm (n)
Primary endpoi
Krishnan 2009 [6] Floseal® (1,603) Length of hospit
Surgicel® + thrombin (17,507)
Gelfoam® + thrombin (10,348)
Other (7,492)
Nasso 2009 [9] Floseal® (209) Rate of successfu
and time require
Topical haemostatic agent
(Surgicel® or Gelfoam®) (206)
Sugarman 2013 [8] Economic comparison with
2009 Nasso study
Economic value w
achieve haemost165 in control group) (the group difference in the maximal
decrease in haemoglobin was 0.96 g/dL, p < 0.0001) [11].
Tonsillectomy and adenoidectomy
Four prospective, randomised trials in tonsillectomy and
adenoidectomy were identified and detailed on Table 6.
Two of these trials were European studies that included
all patients over 16 years of age [12,13].
The other two were US studies and included only chil-
dren (mean age 7.1 years) undergoing adenoidectomy or
adenotonsillectomy [14,15], respectively.
The two US studies included similar number of children
(n = 70 and n = 68) and both concluded that Floseal®-nt Principal results
al stay Floseal® was associated with a lower
likelihood of exceeding the expected




Significantly higher rates of successful
haemostasis and a shorter time to
haemostasis were observed in the Floseal®
group (p < 0.001 both)
hen using Floseal® to
asis
The use of Floseal® resulted in substantial
net cost savings.
Table 5 Orthopaedic surgery
Author and year Comparator and patients
per arm (n)
Primary endpoint Principal results
Comadoll 2012 [11] Floseal® (184) Pre- and postoperative decreases in
haemoglobin decreases
Floseal® resulted in less reduction in haemoglobin
than did the use of conventional haemostatic




Kim 2012 [9] Floseal® (97) Blood loss measured through drain
output
Floseal® had no demonstrable effect on blood loss,
as measured through drain output.
Electrocautery (99)
Velyvis 2012 [10] Floseal® (83) Blood loss measured through drain
output
Floseal® significantly reduced blood loss (p = 0.0001)
and blood transfusion requirements (p = 0.07).
Conventional method (100)
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compared with EC-treated patients (2.5 vs. 29.4 mL,
p < 0.001 [14]; 49.2 vs. 70.8 mL, p < 0.05 [15]).
In children undergoing adenoidectomy, the authors
[14] also concluded that Floseal® application (n = 35)
yielded significantly shorter times to haemostasis (0.6 vs.
9.5 minutes, p < 0.001), significantly less subjective bleeding
(0.0 vs. 2.0, as measured by visual analogue scale, p < 0.001),
and operating surgeons experienced subjectively easier op-
erations than electrocautery (n = 35) [14]. In addition to the
endpoint of blood loss, one study performed from 2004–
2005 concluded that adenotonsillectomy procedures in
which Floseal® was used had significantly shorter operating
times compared with traditional electrocautery (16 vs.
31.2 minutes, p < 0.0001) [15]. In both US studies, Floseal®
application was also associated with significantly less pain
(p < 0.05 for both) and an earlier return to a normal diet
(p < 0.001 and p < 0.01) [14,15].
The European studies were performed in patients over
16 years of age undergoing tonsillectomy. In Blackmore’s
study, the patients (n = 30) were randomised to receiveTable 6 Tonsillectomy and adenoidectomy
Author and year Comparator and patients
per arm (n)
Primary endpoint
Jo 2007 [15] Floseal® (34) Postoperative recove
morbidity
Electrocautery (34)
Blackmore 2008 [12] Ligatures (one fossa
randomised to Floseal® and
the other to ligatures) (30)
Postoperative pain
Mathiasen 2004 [14] Floseal® (35) Time to haemostasis
Cautery (35)
Mozet 2012 [13] Floseal® (89) Handling, duration,
postoperative pain m
healing; and rate of
haemorrhage
Bipolar electrocautery (87)Floseal® on one tonsil fossa, whereas ligatures were per-
formed to achieve haemostasis in the other fossa, which
acted as (the in-patient) control. The aim of this study
was to evaluate postoperative pain with (n = 81) and
without Floseal® use (n = 89), although no statistically sig-
nificant difference was found in postoperative pain scores
when using Floseal® [12]. The second European
investigation randomised patients to receive Floseal® or
electrocautery after tonsillectomy [13]. The patients who
received Floseal® showed significantly improved wound
healing throughout the postoperative period, a trend of
less postoperative pain (not significant, NS), and a signifi-
cantly shorter duration of pain medication use compared
with electrocautery patients (9.5 vs. 11.6 days, p = 0.014),
as well as reduced pain medication consumption/demand
(p = 0.032) [13].
Sinus surgery
Six clinical evaluations of endoscopic sinus surgery (ESS)
were identified, with different study designs (randomisa-
tion of each fossa or patient to a different treatment)Principal results
ry time and Floseal® decreased postoperative pain and
narcotic pain medication use (p < 0.05 both)
and resulted in a faster return to regular diet
and activity (p < 0.01 both). Also shorter
operative times were observed (p < 0.0001)
and less blotod loss (p < 0.05) with Floseal®
No reduction in pain in the Floseal® group.
and blood loss Floseal® yielded significantly shorter times to





The Floseal® group had less postoperative pain
(p = 0.074), a significantly shorter duration of
pain medication use (p = 0.014), and reduced
pain medication consumption/demand
(p = 0.032). Not significant difference in
postoperative haemorrhage.
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surgery type (Table 7). Five of these 6 studies were com-
pleted in North America, and the other one was per-
formed in Europe.
Chandra et al. evaluated the postoperative and long-
term effects of Floseal® (n = 20) in comparison with other
thrombin-soaked gelatine foams (n = 20) [16,17]. The au-
thors concluded that the Floseal® group showed signifi-
cantly increased granulation tissue (p = 0.007) and adhesion
formation (p = 0.006), which are the most common compli-
cations after ESS.
Shrime [18] also analysed ESS with (n = 37) and with-
out (n = 135) Floseal® application. Patients were followed
for 1.3 years after ESS, and the authors concluded that a
significantly higher incidence of synechia formation was
detected in the Floseal® group, resulting in a higher rate
of revision procedures (18.9% vs. 6.7%, p = 0.009).
When Floseal® was compared with Merocel® (synthetic
haemostatic sponge with tamponade effect for nasal
packing) in ESS, the length of hospitalisation was 36%
shorter in the Floseal® group (n = 50), and patient satis-
faction was reported to be much higher in these pa-
tients. Additionally, the removal of Merocel® (n = 50)
caused pain, which was absent during Floseal® use (no
statistical data were provided for this research). The au-
thors concluded that although the cost per application
of Floseal® was €198, compared with €19 for Merocel®,Table 7 Sinus surgery
Author and year Comparator and patients
per arm (n)
Primary endpoi
Chandra 2003 [16] Floseal® (20) Effects on mucos
Thrombin-soaked gelatine
foam (20)




Baumann 2003 [19] Floseal® (50) Intra- and postop
of application, an
stayMerocel® (50)
Jameson 2006 [20] Floseal® (43) Bleeding and hea
Saline-soaked neuropatties (47)
Shrime 2007 [18] Floseal® (37) Incidence and ou
factors for synech
Conventional method (135)
Beyea 2011 [21] Floseal® (10) Nasal bleeding
Hemostase® (8)this difference was largely compensated for by lower
hospitalisation costs in the Swiss population [19].
In a prospective, randomised, double-blinded con-
trolled study of 45 patients undergoing bilateral ESS,
each side was randomly assigned either Floseal® followed
by saline-soaked neurosurgical patties or a control treat-
ment of saline-soaked neurosurgical patties alone [20].
In all, 20 patients received the same treatment on both
sides, whereas 25 patients received a different treatment
on each side. Floseal® treatment resulted in significantly
reduced bleeding in the immediate postoperative period.
Moreover, the average duration of bleeding in the recov-
ery room for Floseal® compared with nasal packing was
reported to be 16.4 minutes and 30.8 minutes, respect-
ively (p = 0.028). In addition, patients reported less pain
on the Floseal® side (p = 0.027) in postoperative diaries.
At a one-week follow-up, sinuses treated with Floseal®
exhibited less crusting than those of controls (2.4% vs.
18.6%, p = 0.015), although this difference resolved by
month 1.
In the most recent of the ESS studies identified, eight-
een patients who underwent ESS were randomised to re-
ceive either Floseal® (n = 10) or Hemostase® (n = 8), a
purified plant polysaccharide [21]. The primary outcome
measure of the study was total operative blood loss. The
study concluded that there were no significant differ-
ences in intraoperative bleeding between the two groups.nt Principal results
al healing Not significant differences in the extent of
surgery or the need for additional nasal
packing. The Floseal® groups showed increased
granulation tissue (p = 0.007) and adhesion
formation (0.006).
-up of previous Floseal®
ndra 2003)
Higher overall incidences of adhesions
(p = 0.013) and adhesions requiring lysis
(p = 0.046) in the Floseal® group.
erative bleeding, cost
d length of hospital
Equal intraoperative haemostasis in both
groups. A 36% shorter length of hospital stay
in the Floseal® group. High postoperative
comfort in the Floseal® group. The higher costs
of Floseal® application were largely
compensated for by the lower hospitalisation
costs.
ling A shorter time to the cessation of bleeding in
the Floseal® group (p = 0.028). Less crusting in
the Floseal® group at 1 week and significantly
less pain on Floseal®-treated patients
(p = 0.027)
tcomes of and risk
ia formation
A higher incidence of synechia formation
in the Floseal® group. Similar intra- and
postoperative complications.
NS difference in blood loss between groups
(p = 0.93).
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the number of nasal pledgets used.
Thyroidectomy
One Italian thyroid surgery study identified in this re-
view (Table 8), included 155 patients between January
2005 and December 2007, and were randomised to re-
ceive one of the following procedures: the surgical pro-
cedure alone (n = 49), Tabotamp Fibrillar® (an oxidised
regenerated cellulose patch) (n = 52), or Floseal® (n = 54)
[22]. The mean operating time was significantly reduced
in the Floseal® group (105 minutes) in comparison with
the other two groups (133 minutes, p = 0.02, for the sur-
gical procedure alone; 122 minutes, p = 0.0003, for Tabo-
tamp®). Additionally, significantly earlier wound drain
removal and shorter postoperative hospital stays oc-
curred in the Floseal® group (p = 0.006 vs. the surgical
procedure alone; p = 0.008 vs. Tabotamp®).
Gynaecologic surgery
Three studies, from Italy, Spain, and Turkey, included
patients undergoing gynaecologic surgery, specificallyTable 8 Other surgery types
Surgery type Author and year Comparator and patie
per arm (n)
Gynaecologic surgery Angioli 2009 [23] Floseal® (8)
Control (bipolar forceps
carbon-dioxide laser) (1
Raga 2009 [24] Floseal® (25)
Isotonic sodium chlorid
Sönmezer 2013 [25] Floseal® (13)
Bipolar electrosurgical
coagulation (15)
Lacrimal surgery Durrani 2007 Floseal® (10)
Without Floseal® (10)
Thyroid surgery Testini 2009 [22] Floseal® (54)
Surgical haemostasis (4
Tabotamp (52)myomectomy or laparoscopic excision of endometrio-
mas, to evaluate the role of Floseal® in intraoperative
blood loss and the time to haemostasis [23-25] (Table 8).
The comparators were different between the studies;
thus, the results also differed. When Floseal® (n = 25)
was compared with isotonic sodium chloride (n = 25)
[24], Floseal® was significantly better due to less intraop-
erative blood loss (25 mL vs. 250 mL, p = 0.001) and no
patients requiring transfusion, in comparison with 20%
of the control group (p < 0.001). However, when the
comparator was a carbon-dioxide laser or bipolar for-
ceps, Floseal® yielded a shorter, but not statistically
significant, time to haemostasis; less blood loss; and a
lower decrease in postoperative haemoglobin [23]. In
the third case [25], bipolar electrosurgical coagulation
(n = 15) was compared with Floseal® (n = 15) to evaluate
the effect on ovarian reserve in patients undergoing lap-
aroscopic endometrioma surgery. Acute ovarian damage
was less common in the Floseal® group during the first
postoperative month, but the ovarian reserve was
replenished in the bipolar electrosurgical coagulation
group by the third month.nts Primary endpoint Principal results
Control of minor
bleeding
Not significant differences in the
time to haemostasis, blood loss, or
the operating time.or
2)
Haemostatic efficacy Less intra- and postoperative blood
loss (p = 0.001) and a lower rate of
transfusions (0% in the Floseal®
group) (p < 0.001) for patients
treated with Floseal®. A shorter
length of hospital stay in the




During the first postoperative
month, ovarian damage was
significantly lower in the Floseal®
group (p < 0.001). However, at the




Nine patients in the Floseal® group
had no or minimal bleeding; this
finding was statistically significant at
all three measured time points
(immediately (p = 0.047), at 12 h
(p = 0.006), and at 24 h after surgery
(p = 0.005)). The Floseal® group also




A significantly shorter operating
time in the Floseal® group than in
the other groups (p < 0.05). More
rapid wound drain removal and a
shorter length of hospital stay in the
Floseal® group compared with the
other groups (p < 0.05 both).
Not significant difference in
postoperative morbidity.
9)
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Six evaluations of urologic procedures were identified.
All were clinical evaluations, two of which also aimed to
estimate the cost savings of each alternative. The pri-
mary endpoints in all of these studies were different and
all details were collected on Table 9.
In two of the studies, the primary objectives were to
determine the differences in complications after laparo-
scopic partial nephrectomy (LPN) with Floseal® applica-
tion compared with conventional methods or Tachosil®
or no use of an HA [27]. In the first case, the Floseal®
group had significantly fewer overall complications (37%
vs. 16%, p = 0.008) [26], and in the second case, the HA
significantly reduced postoperative complications. More
specifically, Tachosil® provided a greater benefit com-
pared with Floseal® [27].
Two American studies compared Floseal® with two dif-
ferent HAs, Surgiflo® and Gelfoam®, and the authors did
not find significant differences in terms of the time to is-
chaemia or blood loss [28,29]. Additionally, Guzzo et al.
[28] concluded that the potential cost saved per case
using Gelfoam® (n = 21) as a substitute for Floseal® (n = 19)
was up to $450 at their institution when performing LPN.
A different surgical procedure was evaluated in a study by
Pace et al. Thirty patients diagnosed with renal cell carcin-
oma who were going to undergo lumbar renal enucleore-
section were randomised to receive Floseal® (n = 15) or
an infrared-sapphire coagulator (ISC) (n = 15) [30]. The
authors observed significantly higher rates of successfulTable 9 Urologic procedures
Author and year Comparator and patients
per arm (n)
Primary endpoint
Gill 2005 [26] Floseal® (63) Reducing haemorrh
No Floseal® (laparoscopic
suturing) (68)
Guzzo 2009 [27] Floseal® (19) Operating and warm
blood loss, postoper
rate, length of hospGelfoam® (21)
Koni 2012 [28] Floseal® (11) Differences in comp
Tachosil® (25)
No use of haemostatic
agents (7)
Nogueira 2008[29] Floseal® (25) Haemostasis and blo
Surgiflo® (10)
Pace 2010 [30] Floseal® (15) Efficacy in achieving
Infrared-sapphire
coagulator (ISC) (15)




Without Floseal® (110)haemostasis and a shorter time to haemostasis (8.1 vs.
12.9 minutes, p < 0.001) in the Floseal® group. Moreover,
the intra- and postoperative average blood loss was lower
in the Floseal® group (25 vs. 46 mL, p < 0.05). In addition,
wound drain removal occurred earlier, particularly the day
after surgery (p = 0.04), and the LOS was shorter in pa-
tients receiving Floseal® (2.5 in the Floseal® group, in com-
parison with 3.5 days in the ISC group, p < 0.05), and both
findings were statistically significant.
Finally, a single-centre, matched comparison of lympha-
denectomies in extraperitoneal radical prostatectomy with
(n = 32) and without (n = 110) Floseal® use was performed
in Austria [31]. The results demonstrated that of the 32
Floseal®-treated patients, one (3.1%) developed symptomatic
lymphocele, in comparison with 16 of 110 (14.5%) non-
Floseal® cases. Four of these patients had to be treated with
percutaneous puncture, and six needed drainage and subse-
quent laparoscopic fenestration. In a cost analysis using the
2011 Euro, the mean cost per patient in the Floseal® group
was €327 compared with the non- Floseal® cost per patient
of €553, resulting in an average difference of €226 per pa-
tient. The authors concluded that Floseal® is cost effective
due to its ability to reduce the likelihood of lymphocele for-
mation and the need for diagnostic CT scans, laparoscopic
fenestration, and subsequent prolonged hospitalisation.
Lacrimal surgery
A British prospective study [32] was performed with the
aim of evaluating the role of Floseal® in terms ofPrincipal results
agic complications NS differences in the mean warm ischaemia time
(p = 0.55), blood loss (p = 0.36), the operating time,
or the length of hospital stay. Floseal® had
significantly fewer overall complications (p = 0.008).
ischaemia times,
ative transfusion
ital stay, and costs
Similar safety and efficacy for the two alternatives,
and Gelfoam® was less expensive than Floseal®.
lications The use of haemostatic agents significantly
reduced postoperative complications. Among
haemostatic agents, TachoSil® provided the best
benefits in terms of postoperative complications.
od loss The ischaemia time (p = 0.148) and blood loss
(p = 0.518) were comparable between the two
groups.
haemostasis Statistically higher rates of successful haemostasis
and a shorter time to haemostasis were observed




Floseal® may be effective in reducing the likelihood of
lymphocele formation after pelvic lymphadenectomy.
Data suggest that Floseal® is cost effective because it
reduces the need for diagnostic TC scans,
laparoscopic fenestration, and subsequent
prolonged hospitalisation.
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undergoing external dacryocystorhinostomy (DCR) (Table 8).
In particular, Floseal® was used during surgery in ten
patients undergoing DCR. Ten additional consecutive
patients underwent DCR without Floseal®. Nine pa-
tients in the Floseal® group had no or minimal bleeding,
and this difference was statistically significant at all
three measured time points (immediately (p = 0.047), at
12 h (p = 0.006), and at 24 h after surgery (p = 0.05)).
The Floseal® group also had less postoperative discom-
fort (p = 0.0001).
Discussion
To our knowledge, this is the first systematic review
examining all clinical and economic studies on Floseal®
use in all surgery types.
In order to avoid exclusion of studies related to seal-
ants consisting of gelatine and matrix components it was
important not to restrict the search strategy too much.
The large number of articles identified in our literature
review could signify the relevance of research in the field
of surgical sealants.
It is important to mention that Floseal® has been eval-
uated in a wide variety of studies that had to be excluded
from this review due to the inclusion criteria. Of the
studies collected, nearly 40% of the studies were dis-
carded. 58 studies were excluded because they included
Floseal® application in their surgical protocols but were
designed to evaluate different surgical techniques, such
as open or laparoscopic surgery but not to specifically
evaluate the effectiveness of Floseal®.
Some limitations can be taken into account concern-
ing this review. Some of them common to any other sys-
tematic reviews, were inherent to the methodology used.
During the present review we faced the difficulty to de-
termine all of the ways of describing Floseal® (such as a
glue or matrix, among others), and therefore, certain
studies may have been missed despite our best efforts.
However, this risk should be minimal because of the
large number of articles that were initially found.
Due to the scarce publications existing in specific sur-
gical interventions such as lacrimal, thyroid, orthopedic
and gynecological surgery, and the small patient sample
size of them, any interpretation and/or extrapolation of
the results should be precautionary done.
Additionally, a few studies that evaluated the efficacy
of Floseal® were not identified during the initial literature
search due to restriction of the publication dates estab-
lished in this research. However, during the secondary
search among the citations of the articles retrieved in
the primary search, it was observed that three studies
were mentioned in many of the reviewed articles. These
three important studies evaluated the role of Floseal® in
ESS, transsphenoidal pituitary surgery, and cardiac surgery[33-35] and concluded that Floseal® use provided statisti-
cally significantly better results in terms of control of post-
operative bleeding and the time to achieve haemostasis
than did the comparators evaluated (cases study [33],
standard of care [34] and Gelfoam® [35]).
This review reflects the difficulty of comparing results
because all 27 finally identified studies revealed a wide
variety of surgery types (cardiac surgery, ESS, LPN, and
adenoidectomy), and comparators (electrocautery, con-
ventional methods, and other HAs). Additionally among
same surgical procedure, also study designs (prospective,
randomised clinical trials, cases and controls, retrospect-
ive chart reviews, and case studies) were varied and primary
and secondary endpoints (the time to achieve haemostasis,
blood loss, patient comfort after surgery, and pain control),
so it implied and extra difficulty to compare results ob-
tained in this research”.
Just only one study included in this review, evaluated
the economic value of Floseal® [8], concretely in cardiac
surgery. Regarding thyroid surgery, the authors sug-
gested that the costs associated with Floseal® therapy are
likely to be offset by a shorter postoperative stay and re-
duced time in the operating theatre [22]. The clinical
benefits provided by Floseal®, in the majority of cases
mentioned here, would probably yield to efficient health-
care resource use and lead to cost savings. However, this
cannot be extrapolated if economic evaluations are not
performed.
Additionally, fifteen studies evaluated the role of Floseal®
in different surgery types, but these studies were excluded
because no comparator was included. The majority of
these studies (53%) were evaluations of urologic proce-
dures, and the authors concluded that Floseal® rapidly
controlled strong bleeding without suturing, which is
highly advantageous to avoid the complicated technique
required for suturing small bleeding vessels [36-41].
Significantly better results for Floseal® were also identi-
fied in 18 of 26 studies (69.23%), and in the majority of the
remaining studies, Floseal® was found not to be inferior to
the comparator in terms of effectiveness. An increasing
number of studies have confirmed the effectiveness of
Floseal® in achieving haemostasis and reducing blood loss
in patients undergoing surgical procedures. Reduction of
both intra- and postoperative blood loss would reduce the
need for blood transfusions and the LOS, and thus greatly
reduce costs.
Fifteen of the 26 clinical evaluations considered in this
review (with the exception of an economic study [8])
included 50 patients or more, and 12 of the studies had
sample sizes of less than 50 patients. Considering the
studies with <50 patients, 66.6% (8) of the results ob-
tained were not significantly better for Floseal®, and the
remaining 33.4% (4) were significantly better. However,
86.6% (13 of 15) of the studies with sample sizes of ≥50
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compared with alternative treatment. Another way to
classify the selected studies is by study design: nearly
60% (16) of the 26 included clinical evaluations were
prospective, randomised clinical trials, and 26% (7) were
case–control studies. Additionally, 14% (3) of the clinical
evaluations were retrospective chart reviews.
Conclusion
Floseal® has been demonstrated to be an efficacious al-
ternative method in surgical procedures to obtain a
complete and stable haemostasis and also in terms of re-
ducing the time to achieve it, intra- and postoperative
bleeding, and the length of hospital stay, among other
primary outcomes, resulting in less consumption of
health resources. Reduction in healthcare resource use
seems to be associated with a decrease in patient man-
agement costs; thus, the use of Floseal® might even yield
cost savings.
In any case, economic evaluations could be interesting
to assess the resource consumption associated to Floseal®
utilization. The development of further studies at local
level should be performed to confirm that the costs of
using Floseal® would be balanced by a reduction in the use
of health resources.Additional file
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